|
The therapies being developed by Symphony Medical address three highly significant global markets in the cardiovascular medicine sector:
Atrial fibrillation
What is the AHA's position on AF?
"A substantial increase in U.S. hospitalization for atrial fibrillation, the most common sustained irregular herat beat, will be a staggering burden on public health and patients' quality of life ..."
Circulation: July 29, 2003
What are the AF Statistics?
- >5 million persons affected in the US
- >1.2 million hospitalizations
- ~400,000 anual deaths
- >10% annual growth rate
Medtech Insight: US Markets for Arrhythmia Products, January 2005
Atrial fibrillation (AF) is the most common of cardiac abnormalities with an estimated 2.3 million Americans diagnosed. In part based on an aging population, approximately 160,000 new cases are diagnosed each year and the AF population is expected to double by 2050.
The Company's initial product for the prevention of post-operative atrial fibrillation (POAF), Plexisyl-AF™, targets 600,000 cardiac surgical procedures representing an annual market potential of $260 million in the U.S. alone.
Our second arrhythmia product, a catheter-based biotherapeutic delivered to the AV-nodal region of the heart, addresses the treatment of approximately 1 million chronic AF patients who do not respond well to medications such as beta blockers and amiodarone.
Competitors in the AF segment can be divided into drug companies that market rate control drugs like beta blockers, amiodarone, etc., and device companies providing pacing, ablation, and implantable defibrillation systems.
In addition to the POAF patient population for which currently no effective treatment options exist, Symphony Medical ’s catheter-based biotherapeutic product promises to effectively treat a significant AF patient segment that responds sub-optimally to drug treatment regimens as well as those AF patients who currently have no option but to be subjected to invasive cardiac ablation and pacemaker implantation.
With a practical and cost-effective approach, Symphony Medical ’s products are designed to correct cardiac conduction disorders through safe biologic, non-destructive, non-ablative means.
Heart Failure
Heart failure is a serious condition in which a patient's heart begins to lose its blood-pumping capacity. In most patients, the heart's left ventricle which is responsible for pumping oxygen-rich blood out to the rest of the body is affected. Scientists estimate that 5 million people in the U.S. have heart failure and more than half a million patients are diagnosed annually. The condition contributes to 300,000 deaths each year. Heart failure is most common in those who are age 65 years and older and is the number one reason older people are hospitalized. While the technologies of Symphony Medical do not target the entire population of heart failure patients, our potential is estimated at more than 2 million individuals.
|
Printer Friendly
